Profound Medical Corp. (PROF) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with improved gross margins and revenue growth. The CAPTAIN trial data and positive feedback from physicians enhance confidence in TULSA's efficacy. Although there are increased operating expenses and net losses, management's optimistic guidance, strategic partnerships, and successful marketing initiatives signal potential for growth. The Q&A session confirms positive sentiment, with plans for reduced cash burn and strategic expansions. The absence of negative guidance, coupled with favorable reimbursement scenarios, supports a positive outlook for the stock price over the next two weeks.
Key Financial Performance
Total Orders Over $3 million for Q2 2025.
Revenue $2.2 million in Q2 2025, with $1.6 million from recurring revenue and $650,000 from one-time capital equipment sales. Revenue was essentially unchanged year-over-year from Q2 2024.
Gross Margin 73% in Q2 2025, up from 64% in Q2 2024. The increase is attributed to operational efficiencies or changes in revenue mix.
Operating Expenses $15.4 million in Q2 2025, up from $9.3 million in Q2 2024. The increase is due to higher R&D and SG&A expenses.
Net Loss $15.7 million or $0.52 per share in Q2 2025, compared to $6.9 million or $0.28 per share in Q2 2024. The larger loss is due to increased operating expenses.
Cash Position $35.2 million as of June 30, 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
TULSA-AI volume reduction software: Pilot release of the new software designed for BPH procedures was achieved. It offers fast intelligent workflows with an estimated total procedure time of 60 to 90 minutes. The first commercial BPH procedure using this software was performed in June, with a full commercial launch expected in the second half of 2025.
CAPTAIN trial: The trial is fully recruited with 212 patients treated, surpassing the initial target of 201. Initial perioperative outcomes show TULSA provides superior patient experience compared to robotic surgery. Final results are expected to be announced in December 2025.
TULSA adoption and utilization: The CAPTAIN trial and TULSA-AI software are expected to drive adoption and utilization of the TULSA procedure in the U.S. and globally. Inclusion in professional society guidelines is anticipated to increase awareness and adoption.
Sales team restructuring: The U.S. sales team was streamlined, eliminating the director sales level and honing the regional business director and capital sales executive teams. This restructuring aims to improve efficiency and focus on building a larger sales funnel.
Transition to capital model: The company transitioned from a placement model to a capital model in 2025, which is expected to result in back-end loaded operations and significant growth in the second half of the year.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Shortfall: The company reported Q2 revenues below expectations due to delays in completing TULSA-PRO capital sales. This could impact financial performance if delays persist.
Increased Operating Expenses: Operating expenses rose significantly to $15.4 million in Q2 2025 from $9.3 million in Q2 2024, contributing to a higher net loss. This could strain financial resources if not managed effectively.
Transition to Capital Model: The shift from a placement model to a capital model has created a back-end loaded operation, which may lead to uneven revenue recognition and operational challenges.
Sales Team Restructuring: The U.S. sales team was streamlined, eliminating director-level positions. While intended to improve efficiency, this restructuring could disrupt sales operations in the short term.
Dependence on CAPTAIN Trial Outcomes: The company's future success heavily relies on the CAPTAIN trial results to gain favorable treatment guidelines and reimbursement coverage. Any unfavorable outcomes could hinder adoption and financial performance.
Regulatory and Reimbursement Risks: The company is awaiting inclusion in professional society guidelines and positive reimbursement coverage. Delays or denials could limit market adoption of TULSA.
Competitive Pressures: The company faces competition from established treatments like robotic surgery and radiation therapy. Failure to demonstrate clear advantages could impact market share.
Economic and Bureaucratic Challenges: Targeting corporatized bureaucratic hospitals in the U.S. presents challenges in navigating complex organizational sales processes, potentially delaying adoption.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects to deliver 70% to 75% revenue growth in 2025 compared to 2024, driven by a large and growing TULSA-PRO pipeline and stabilized sales team.
TULSA-PRO Sales Pipeline: The sales pipeline includes close to 500 prospects in the targeting stage, with 100+ leads engaged and 80 qualified leads. The company anticipates significant and material improvement in the second half of 2025.
CAPTAIN Trial Outcomes: Initial clinical outcomes data from the CAPTAIN trial will be presented in December 2025, with expectations that the data will lead to new guidelines from relevant cancer societies, requiring patients to be informed about TULSA as a treatment option.
TULSA-AI Volume Reduction Software: The new software module for BPH procedures is expected to launch commercially in the second half of 2025, reducing procedure time to 60-90 minutes and making TULSA more competitive in the BPH treatment market.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details on the guidance and the sales contribution from recurring and capital perspectives?
A:Management reiterated the prior range and explained that the revenue mix is shifting from recurring revenue to capital revenue. Currently, recurring revenue dominates, but over the long term, they expect 70% recurring revenue and 30% capital revenue. They also noted a 10% increase in same-store procedures from Q1 to Q2.
Q:What feedback are you receiving from physicians regarding the CAPTAIN data?
A:Management reported very positive feedback from physicians, highlighting the completion of the clinical trial as a significant achievement. They noted confidence in the outcomes, supported by better results in the TACT trial and improvements in their product.
Q:Can you shed light on the proposed rule for reimbursement on BPH treatments and its impact on the TULSA procedure?
A:The proposed CMS rule for 2026 showed downward adjustments for other BPH procedures, while TULSA was minimally impacted. TULSA maintained favorable reimbursement levels and offers better physician payment per unit time. The feedback from facilities and physicians has been positive.
Q:Can you provide more details on the sales funnel, particularly the contracting stage?
A:Management explained that the contracting stage involves multiple departments and is more complex due to the newness of the capital sales model. The average time for contracting is 3-4 months, and efforts are being made to streamline the process and reduce timelines.
Q:Will the streamlining of the sales force lead to a reduction in cash burn?
A:Yes, management expects lower cash burn in the second half of the year due to adjustments in the sales team and increased inventory to fulfill future orders. Gross margins remain strong at over 70%.
Q:What is the current number of active TULSA placements in the U.S., and how many have been added recently?
A:There are about 60 active sites, with 3 installations in progress. Management is confident in reaching at least 75 active sites by the end of the year.
Q:What updates are there on the TULSA-PLUS model?
A:Management remains optimistic about the TULSA-PLUS model. They expect at least one installation by the end of the year and are working on compatibility with Siemens interventional magnets. They highlighted strategic partnerships with Cook Medical and Siemens to drive adoption.
Q:How are the new marketing initiatives, including the hiring of a spokesperson, performing?
A:Management is pleased with the results and plans to expand their presence on social media as top-line growth continues. They are excited about the impact of their spokesperson and the adjustments made to the marketing team.
Q:Are there any longitudinal studies or localized clinical trials that could drive awareness of TULSA-PRO's utility?
A:Yes, Profound has an international CARE Registry and ongoing studies at various sites. They have had at least 12 presentations at major society meetings this year, showcasing data from CAPTAIN, CARE Registry, and other real-world usage.
Q:Is there any pushback from potential customers regarding systemic therapies for prostate cancer versus TULSA-PRO?
A:Management believes TULSA-PRO and systemic therapies are complementary. They highlighted advancements in diagnostics and the potential for TULSA to play a prominent role in combination with systemic therapies.
Q:How is the soft launch of the volume reduction module for BPH going?
A:The feedback has been excellent, with procedure times meeting the target of 60-90 minutes. The pilot launch is ongoing at 4-5 sites, and the full launch is planned for Q4.
Q:What can we expect from the next updates on CAPTAIN data?
A:Management plans to present complete perioperative outcomes and potentially interim data on safety, quality of life, and efficacy outcomes at RSNA and SUO. These updates will support discussions with professional societies and payers.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the average time between contracting and installation, as well as the average conversion rate. They also used vague language when discussing the streamlining of the contracting phase and the exact impact of the proposed CMS rule changes on TULSA's competitive positioning.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI volume
AUA
Annual Meeting
Arun
BPH patient
BPH procedure
Inc Research
International
Research Division
blood loss
cancer BPH
capital sale
contracting stage
director capital
endpoint
executive
experience
lead
outcome patient
patient study
patient surgeon
pilot release
recovery
reduction software
role
sale funnel
sale process
score
success
surgeon hospital
surgery
team
treatment option
trial treatment
verify
volume reduction
week
PROF Transcript
Profound Medical Corp. (PRN:CA) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call presented strong financial performance with a 104% revenue increase YoY and improved gross margins. Despite a net loss, the reduction is notable. The Q&A highlighted a strong sales pipeline and positive reimbursement rates from private payers. While guidance was conservative, the company's bullish outlook and solid pipeline suggest potential growth. The market's response may be positive, especially with the anticipation of guideline recognition and commercial payer coverage. However, challenges in MR system integration and competitive pressures should be monitored. Overall, the sentiment leans towards a positive stock price movement.
Profound Medical Corp. (PRN:CA) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call reveals strong financial performance with an 87% revenue increase and improved gross margins. Positive guidance with 70%-75% growth expectations, supported by a robust pipeline, indicates optimism. The Q&A highlights significant commercial payer rates and Medicare reimbursement progress, enhancing profitability potential. While there are competitive and operational risks, the company's strategic focus on reimbursement and market access, along with promising clinical outcomes, supports a positive outlook. Despite some management vagueness, the overall sentiment is positive, likely resulting in a 2%-8% stock price increase.
Profound Medical Corp. (PROF) Q2 2025 Earnings Call Transcript
Positive8-14
The earnings call highlights strong financial performance with improved gross margins and revenue growth. The CAPTAIN trial data and positive feedback from physicians enhance confidence in TULSA's efficacy. Although there are increased operating expenses and net losses, management's optimistic guidance, strategic partnerships, and successful marketing initiatives signal potential for growth. The Q&A session confirms positive sentiment, with plans for reduced cash burn and strategic expansions. The absence of negative guidance, coupled with favorable reimbursement scenarios, supports a positive outlook for the stock price over the next two weeks.
Profound Medical Corporation (PROF) Q1 2025 Earnings Conference Call Transcript
Unknown5-9
The earnings call presents a mixed picture: strong revenue growth and promising product development (TULSA AI and CAPTAIN trial) are offset by increased net losses and operating expenses. The Q&A section reveals positive feedback on CAPTAIN data and insurer engagement, but management's vague responses on deal closures and financial guidance introduce uncertainty. The lack of shareholder return initiatives further tempers optimism. Despite potential for future growth, current financial instability and competitive pressures suggest a neutral stock price movement in the short term.
PROF Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
